SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Maulcoin

Maulcoin is trending as its community aggressively rallies to push the token past key market capitalization milestones through active social engagement and coordinated buying challenges. Investors are drawn to the project's 'dark side' aesthetic and anti-rug pull narrative, which focuses on organic growth rather than traditional charts or celebrity-driven hype.

ESH Acquisition Corp. is a blank check company. It was formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. The company was founded on November 17, 2021 and is headquartered in New York, NY.

ESH Acquisition Corp - Ordinary Shares - Class A

ESH Acquisition Corp is experiencing significant investor interest driven by its status as a low-float SPAC, leading to high volatility and multiple trading halts. The community is actively debating the potential for a massive price squeeze, with many users drawing parallels to other recent high-momentum SPAC runs while debating the sustainability of the current price action.

Alexandria Real Estate Equities, Inc. engages in the provision of space for lease. It offers properties for rent to life science, agriculture technology (agtech), and technology tenants. The company was founded by Alan D. Gold, Gary A. Kreitzer, Joel S. Marcus, and Jerry M. Sudarsky in October 1994 and is headquartered in Pasadena, CA.

Alexandria Real Estate Equities Inc.

Alexandria Real Estate Equities (ARE) is currently drawing significant attention from investors who view the stock as deeply undervalued due to its historically low price-to-FFO ratios and substantial discounts to net asset value despite owning premium life science assets. While the broader market sentiment remains cautious regarding high interest rates and biotech sector headwinds, the community is actively debating whether current levels represent a generational buying opportunity or a deeper long-term correction.

PENGU is the official coin of Pudgy Penguins.  Pudgy Penguins has become the face of crypto with one of the most influential communities in the industry. From large companies wearing the Penguin, to being featured in ETF commercials, to garnering millions of followers and over 100 billion views, the Pengu has become a cultural icon making PENGU the world’s social currency.  PENGU allows for the ever-expanding Pudgy Penguin fanbase and the hundreds of millions of people outside of crypto that see and share the Pudgy Penguin everyday, to join The Huddle. PENGU is a symbol for community, memes, and good vibes.  Believe in Pengu. Believe in the Prophecy.

Pudgy Penguins

Pudgy Penguins is trending as investors highlight its "phygital" brand strategy, specifically citing its massive retail presence in major chains and the launch of the Pengu Visa Card as key drivers for long-term utility. The community is actively discussing accumulation opportunities and comparing the project's unique revenue-generating model against traditional meme coins during this market phase.

Shell Plc engages in the business of producing oil and natural gas. It operates through the following segments: Integrated Gas, Upstream, Marketing, Chemicals and Products, Renewables and Energy Solutions, and Corporate. The Integrated Gas segment includes liquefied natural gas, and conversion of natural gas into gas-to-liquids fuels. The Upstream segment focuses on exploration and extraction of crude oil, natural gas, and natural gas liquids. The Marketing segment is involved in mobility, lubricants, and sectors and decarbonization businesses. The Chemicals and Products segment consists of chemicals manufacturing plants with marketing network and refineries, which turn crude oil and other feedstocks into a range of oil products. The Renewables and Energy Solutions segment provides renewable power generation, marketing, trading, and optimizing power and pipeline gas, as well as carbon credits and digitally enabled customer solutions. The Corporate segment covers non-operating activities supporting Shell such as holdings, treasury organization, self-insurance activities, and headquarters and central functions. The company was founded in February 1907 and is headquartered in London, the United Kingdom.

Shell Plc - ADR (Representing - Ordinary Shares)

Shell is currently in the spotlight after the Dutch Court of Appeal overturned a landmark 2021 ruling that previously mandated the company to sharply reduce its carbon emissions. While investors and market participants are parsing the implications of this legal win on Shell's climate strategy and capital allocation, the stock continues to be influenced by broader energy sector volatility and the firm's ongoing efforts to balance transition goals with core fossil fuel profitability.

Aon Plc engages in the provision of risk, health, and wealth solutions. It focuses on risk capital including claim management, reinsurance, risk analysis, management, retention, and transfer; and human capital involving analytics, health and benefits, investments, pensions and retirement, talent and rewards, and workplace wellbeing. The company was founded in 1982 and is headquartered in Dublin, Ireland.

Aon plc. - Ordinary Shares - Class A

Aon is trending after its recent earnings report revealed a beat on EPS but a miss on revenue, sparking community debate over financial consistency despite strong organic growth in its Reinsurance Solutions segment and management's optimistic outlook for the coming year.

SPDR Series Trust - State Street SPDR S&P Semiconductor ETF

SPDR S&P Semiconductors ETF

The SPDR S&P Semiconductor ETF (XSD) is drawing significant attention as investors analyze whether recent semiconductor sector volatility represents a healthy consolidation or a deeper market shift. Community sentiment remains mixed, with some traders leveraging technical signals like "cup and handle" patterns and institutional buying flow to justify bullish positions, while skeptics point to earnings performance gaps and broader macroeconomic risks as reasons to remain cautious.

DRDGOLD Ltd. engages in the business of retreatment of surface gold. The company was founded on February 16, 1895, and is headquartered in Johannesburg, South Africa.

DRDGold Ltd. - ADR

DRDGOLD Ltd.

DRDGOLD Ltd. is seeing strong investor interest as gold prices stabilize and market participants look for inflation-hedging opportunities within the mining sector. Community discussions are centered on the stock's operational efficiency, its role as a high-growth dividend play, and its potential for institutional accumulation alongside broader momentum in precious metals.

Fidelity Wise Origin Bitcoin Fund - Fidelity Wise Origin Bitcoin Fund Beneficial Interest

Fidelity Wise Origin Bitcoin Fund

Cadence Design Systems, Inc. engages in the provision of design and development of integrated circuits and electronic devices. It operates through the following geographical segments: Americas, Asia, EMEA, and Japan. The company was founded by Alberto Sangiovanni-Vincentelli, Gudmundur A. Hjartarson, K. Bobby Chao, and K. Charles Janac in June 1988 and is headquartered in San Jose, CA.

Cadence Design Systems, Inc.

Cadence Design Systems is currently at the center of a debate regarding whether the stock is a victim of broad-based selling in the software sector or a strategic opportunity in the semiconductor design space. While some investors are expressing caution due to technical pressure and valuation concerns, others are highlighting the company's indispensable role as an architect of AI chip innovation, viewing the recent volatility as a potential setup for a long-term recovery.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Insmed (NASDAQ:INSM) Upgraded to "Moderate Buy" at Raymond James Financial

Raymond James Financial raised shares of Insmed to a "moderate buy" rating in a research report on Thursday...

Raymond James Financial Initiates Coverage on Insmed (NASDAQ:INSM)

Raymond James Financial started coverage on Insmed in a research note on Friday. They issued an "outperform" rating and a $200.00 target price on the stock...

What is HC Wainwright's Estimate for Insmed FY2027 Earnings?

Insmed, Inc. (NASDAQ:INSM - Free Report) - Research analysts at HC Wainwright lifted their FY2027 earnings per share (EPS) estimates for Insmed in a research report issued on Wednesday, April 8th. HC Wainwright analyst A. Fein now forecasts that the biopharmaceutical company will earn $0.88 per shar...

Insmed (NASDAQ:INSM) CEO Sells $1,746,290.78 in Stock

Insmed, Inc. (NASDAQ:INSM - Get Free Report) CEO William Lewis sold 10,699 shares of Insmed stock in a transaction that occurred on Monday, April 6th. The shares were sold at an average price of...

Insmed (NASDAQ:INSM) CEO William Lewis Sells 10,699 Shares

Insmed, Inc. (NASDAQ:INSM - Get Free Report) CEO William Lewis sold 10,699 shares of the company's stock in a transaction on Monday, April 6th. The shares were sold at an average price of $163.22...

Insmed Ends Brinsupri Development in Skin Disease Post Study Failure

INSM scraps Brinsupri for HS after phase IIb failure, with placebo outperforming treatment despite no safety issues.

Insmed Drug Misses Primary Goal, Program Axed

Insmed halts HS program after CEDAR study miss; analysts cite trial challenges while focus shifts to Brinsupri and Arikayce growth drivers.read more...

<ul class="summary-bullets"><li>Insmed said that it will subsequently discontinue development of brensocatib in hidradenitis suppurativa</li><li>Martina Flammer, Chief Medical Officer of Insmed, said that the company was disappointed with the results.</li><li>According to data from Koyfin, &nbsp;all of the 20 analysts covering INSM stock rate it ‘Buy’ or higher.</li></ul>Insmed Incorporated (INSM) said on Tuesday that its mid-stage study evaluating brensocatib in adult patients with moderate to severe hidradenitis suppurativa failed to meet its goals.Shares of the company fell 2% after hours.<h2 class="st-heading-2">Study Results</h2>The mid-stage trial was aimed at evaluating the safety and efficacy of brensocatib in adults with moderate to severe hidradenitis suppurativa, a chronic, non-contagious inflammatory skin condition characterized by painful, recurring lumps and abscesses. &nbsp;The trial did not meet the primary or secondary endpoints in either the 10 mg or 40 mg treatment arms though the drug was well tolerated, the company said. The study enrolled 214 patients and its primary goal was a reduction in total abscess and inflammatory nodule at 16 weeks.Participants of the study experienced a 45.5% and 40.3% reduction from baseline in total abscess and inflammatory nodule (AN) count in the brensocatib 10 mg and 40 mg arms, respectively, compared to a 57.1% reduction in the placebo arm, the company said.Insmed said that it will subsequently discontinue development of brensocatib in hidradenitis suppurativa. Martina Flammer, Chief Medical Officer of Insmed, said that the company is “disappointed” with the results.<h2 class="st-heading-2">How Did Retail Traders React?</h2>On Stocktwits, retail sentiment around INSM stock stayed within the ‘bearish’ territory over the past 24 hours, while message volume fell from ‘high’ to ‘normal’ levels.According to data from Koyfin, all 20 analysts covering INSM stock rate it ‘Buy’ or higher. The stock has an average 12-month price target of $214.79, representing a potential upside of about 32% from last closing price.The company currently has two approved therapies, including Brinsupri for the treatment of non-cystic fibrosis bronchiectasis (NCFB) in adults and children 12 years and older, and Arikayce for the treatment of certain Mycobacterium avium complex (MAC) lung infections.<a href="https://stocktwits.com/symbol/INSM">INSM stock</a> has more than doubled over the past 12 months. &nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/gopro-shares-edge-up-after-hours-on-23-percent-layoff-announcement/cZJB2feRIqd">GoPro Shares Edge Up After-Hours On 23% Layoff Announcement</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Insmed Incorporated logo is seen displayed on a smartphone. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

INSM Stock Dips In Extended Trading After Experimental Skin Disease Drug Fails In Study 

The trial did not meet the trials’s primary or secondary endpoints in either the 10 mg or 40 mg treatment arms, though the drug was well tolerated, the company said. 

Equity

The trial did not meet the trials’s primary or secondary endpoints in either the 10 mg or 40 mg treatment arms, though the drug was well tolerated, the company said. 


Insmed Provides Clinical Update on Phase 2b CEDAR Study

Insmed Provides Clinical Update on Phase 2b CEDAR Study Insmed Provides Clinical Update on Phase 2b CEDAR Study PR Newswire BRIDGEWATER, N.J., April 7, 2026 Study Did Not MeetPrimary or Secondary...

The death cross is one of the most closely watched patterns in technical analysis. It forms when a stock's 50-day moving average crosses below its 200-day moving average. Image courtesy: Getty Images

INSM, FSLR, APTV: Dreaded Death Cross Has Formed On These Stocks — What It Means For Investors

Bearish technical signals flash across three stocks, but Wall Street analysts still see meaningful upside ahead.

Insmed, Inc. is a global biopharmaceutical company, which engages in the development and commercialization of therapies for patients with rare diseases. Its focuses on Brensocatib, and Treprostinil Palmitil Inhalation Powder (TPIP) pipeline. The company was founded in 1988 and is headquartered in Bridgewater, NJ.

INSM
Insmed Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest INSM News

INSMInsmed Inc